The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Teskey noted that Brookfield's latest flagship rounds, including the Global Transition Fund and Real Estate flagship fund, are slated for final close in the first half of 2025. Complementary ...